EU/3/19/2145 - orphan designation for treatment of spinal muscular atrophy
Risdiplam
OrphanHuman
Overview
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in September 2023 upon request of the marketing authorisation holder.
On 26 February 2019, orphan designation (EU/3/19/2145) was granted by the European Commission to Roche Registration GmbH, Germany, for risdiplam for the treatment of spinal muscular atrophy.
Risdiplam has been authorised in the EU as Evrysdi since 26 March 2021.
Spinal muscular atrophy is an inherited disease usually diagnosed in the first year of life that affects the motor neurons (nerves from the brain and spinal cord that control muscle movements). Patients with the disease lack a protein called ‘survival motor neuron’ (SMN), which is essential for the normal functioning and survival of motor neurons. Without this protein, the motor neurons deteriorate and eventually die. This causes the muscles to fall into disuse, leading to muscle wasting (atrophy) and weakness.
Spinal muscular atrophy is a long-term debilitating and life-threatening disease because it causes breathing problems and muscle wasting that worsens over time.
At the time of designation, spinal muscular atrophy affected approximately 0.4 in 10,000 people in the European Union (EU). This was equivalent to a total of 21,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).
*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. This represents a population of 518,400,000 (Eurostat 2019).
At the time of designation, the medicine Spinraza (nusinersen) was authorised for the treatment of spinal muscular atrophy. Spinraza is given by injection into the spine. Patients also received supportive treatment to help them and their families cope with the symptoms of the disease. This included chest physiotherapy and physical aids to support muscle function, and ventilators to help with breathing.
The sponsor has provided sufficient information to show that the medicine might be of significant benefit for patients with spinal muscular atrophy. Early data indicate that the medicine may improve patients’ survival and muscle strength compared with results seen with the authorised treatment; additionally, since the medicine is to be given by mouth, it may be usable in a broader population. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.
The SMN protein can be made by two genes, SMN1 and SMN2. Patients with spinal muscular atrophy lack a working SMN1 gene but have the SMN2 gene, which mostly produces a short SMN protein that does not work as well as a full-length protein.
Risdiplam is a small molecule that enables the SMN2 gene to produce a full length protein, which is able to work normally. This is expected to increase survival of motor neurons and reduce symptoms of the disease.
The effects of risdiplam have been evaluated in experimental models.
At the time of submission of the application for orphan designation, clinical trials with risdiplam in patients with spinal muscular atrophy were ongoing.
At the time of submission, risdiplam was not authorised anywhere in the EU for spinal muscular atrophy. Orphan designation of risdiplam had been granted in the United States and Switzerland for this condition.
In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 24 January 2019 recommending the granting of this designation.
- the seriousness of the condition;
- the existence of alternative methods of diagnosis, prevention or treatment;
- either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.
Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.
Key facts
- Active substance
- Risdiplam
- Intended use
- Treatment of spinal muscular atrophy
- Orphan designation status
- Withdrawn
- EU designation number
- EU/3/19/2145
- Date of designation
- Sponsor
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Baden-Wuerttemberg
Germany
E-mail: info.orphan@roche.com
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Evrysdi at the time of marketing authorisation, and confirmed that the orphan designation should be maintained.
More information is available in the Evrysdi : Orphan maintenance assessment report (initial authorisation).
Update history
| Date | Update |
|---|---|
| September 2023 | The product was withdrawn from the Community Register of designated orphan medicinal products upon request of the marketing authorisation holder. |
EMA list of opinions on orphan medicinal product designation
EMA publishes information on orphan medicinal product designation adopted by the Committee for Orphan Medicinal Products (COMP) on the IRIS online platform:
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: